We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 22, 2020

Everolimus for Recurrent, Radiographic-Progressive NF1-Associated Pediatric Low-Grade Glioma



Additional Info

Disclosure statements are available on the authors' profiles:

A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1–Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study
Neuro-oncology 2020 Oct 14;22(10)1527-1535, NJ Ullrich, SP Prabhu, AT Reddy, MJ Fisher, R Packer, S Goldman, NJ Robison, DH Gutmann, DH Viskochil, JC Allen, B Korf, A Cantor, G Cutter, C Thomas, JP Perentesis, T Mizuno, AA Vinks, PE Manley, SN Chi, MW Kieran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading